Barclays Has Lowered Expectations for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price target reduced by research analysts at Barclays from $23.00 to $21.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price objective would indicate a potential downside of 1.20% from the company’s current price.

KVUE has been the topic of a number of other research reports. Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. UBS Group reduced their price target on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Jefferies Financial Group initiated coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Up 0.3 %

KVUE traded up $0.07 on Friday, reaching $21.26. The company’s stock had a trading volume of 3,168,614 shares, compared to its average volume of 8,549,094. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The business’s 50 day moving average is $22.47 and its 200 day moving average is $21.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market cap of $40.75 billion, a price-to-earnings ratio of 38.61, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 earnings per share. As a group, research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Kenvue

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Genesis Private Wealth LLC bought a new position in Kenvue during the fourth quarter valued at about $251,000. Atomi Financial Group Inc. lifted its holdings in Kenvue by 28.1% in the 4th quarter. Atomi Financial Group Inc. now owns 11,730 shares of the company’s stock worth $250,000 after purchasing an additional 2,571 shares during the last quarter. Kiley Juergens Wealth Management LLC boosted its position in Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares during the period. LaFleur & Godfrey LLC grew its holdings in Kenvue by 29.8% during the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company’s stock valued at $1,736,000 after purchasing an additional 18,650 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in Kenvue by 184.3% during the fourth quarter. UMB Bank n.a. now owns 3,651 shares of the company’s stock valued at $78,000 after purchasing an additional 2,367 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.